Loading…
Loading…
how durable is this double-digit growth in a category that's, you know, a pacemaker, low single-digit growth category
where are we from a penetration standpoint? What innings are we in?
What percentage of your installed base has been updated or convert to a -- where are we in the conversion cycle
What drives the back half acceleration rate when we look at Q1 starting point of 7%
your gross margins are still below pre-pandemic levels. So, I'm curious, when you look at the margins, how sustainable are these trends
how are you thinking of M&A versus share repurchases, right, when you look at assets available in the deal pipeline
your guide implies for Q4 double digits. So maybe talk about what changes sequentially from 3Q to 4Q
Implied growth of Q4 should accelerate to, you know, high singles, maybe 8 to 9%
Was there any pull forward either in academic channels or biopharma channels
The $350 million of that gross headwinds, is that a full year impact or a partial year impact
What is Danaher's total exposure to pharma, pharma overall, including bioprocessing
How much of that is being contemplated in Q1 and rest of the year? And can you just remind us on - of your M&A criteria
Was there anything one-off in Q1, maybe which is different versus the rest of the year? I think you mentioned, Pall